產後憂鬱症市場規模、佔有率和成長分析：按療法、藥物類別、給藥途徑、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球產後憂鬱症市場價值為 42.1 億美元，預計到 2025 年將成長至 46.8 億美元，到 2033 年將成長至 109.5 億美元，在預測期（2026-2033 年）內複合年成長率為 11.2%。

全球產後憂鬱症(PPD) 市場涵蓋藥品、數位療法和支持服務，旨在診斷和治療產後憂鬱症發作。大約七分之一的母親會受到影響，這種疾病會因生產力下降而造成巨大的經濟負擔。儘管該市場先前主要由非專利抗憂鬱症主導且較為分散，但隨著人們對產後憂鬱症的認知不斷提高，以及流行病學研究加強了篩檢和診斷，該市場正在發生變化。數位健康解決方案的興起是推動擴充性治療方案的關鍵趨勢。醫療服務提供者正在採用遠距精神科服務以獲得保險報銷，而新創公司則正在利用人工智慧工具及早識別風險。此外，製藥公司正在與數位平台合作，開發藥物依從性監測應用程式，從而建立一個促進患者就醫和市場成長的協作生態系統。

全球產後憂鬱症市場成長要素

全球產後憂鬱症市場正受到旨在促進早期發現疾病的意識提升和教育活動的顯著影響。主動篩檢計畫的出現，使母親能夠及時獲得治療性介入，從而減輕長期影響。醫療保健專業人員正在將常規心理健康評估納入產後護理，以創造一個支持性的環境，讓母親能夠自在地談論她們的症狀。這種意識的提高不僅改善了患者的健康狀況，也增加了對各種診斷工具、諮詢服務和藥物治療方案的需求。因此，專業治療途徑的使用和接受度正在提高，從而推動了市場成長。

全球產後憂鬱症市場的限制因素

全球產後憂鬱症市場面臨嚴峻挑戰，這主要是由於持續存在的社會污名和根深蒂固的文化誤解。許多女性難以辨識和承認產後憂鬱症的症狀，她們往往擔心尋求協助會被視為個人失敗。這導致她們孤立無援，最終得不到治療，嚴重限制了她們獲得治療性介入、諮詢服務和藥物的機會。此外，缺乏全面的社區宣傳活動加劇了這些焦慮，阻礙了關於產婦心理健康的公開溝通。因此，這些因素共同阻礙了市場成長，並降低了對必要支持和治療的整體需求。

全球產後憂鬱症市場趨勢

全球產後憂鬱症市場正呈現出顯著的數位化療法應用趨勢，這主要得益於遠端醫療和行動醫療解決方案的日益普及。臨床醫生擴大採用循證的、主導應用程式的干預措施，這些措施提供認知行為療法、情緒追蹤和同儕支持，從而增強患者參與度並消除地域障礙。這些創新平台透過先進的數據分析實現個人化治療方案，從而促進以患者為中心的護理模式。隨著法律規範的調整，將「醫療設備軟體（SaM）」納入核准範圍，醫療服務提供者對虛擬護理解決方案的安全性和有效性越來越有信心，這不僅擴大了市場機遇，也改善了受影響人群的就醫途徑。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球產後憂鬱症市場規模：依治療類型分類

• 藥物治療
• 心理治療
• 神經調控療法
• 聯合治療

全球產後憂鬱症市場規模：依藥物類別分類

• 選擇性血清素再回收抑制劑（SSRIs）
• 神經活性類固醇
• 正腎上腺素再回收抑制劑（SNRIs）
• 三環抗憂鬱藥物（TCAs）
• 其他

全球產後憂鬱症市場規模：依給藥途徑分類

• 口服
• 靜脈注射（IV）
• 鼻內給藥

全球產後憂鬱症市場規模：依分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球產後憂鬱症市場規模：依最終用戶分類

• 醫院
• 專科診所
• 門診部
• 居家醫療

全球產後憂鬱症市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Sage Therapeutics Inc.
• Biogen Inc.
• Pfizer Inc.
• Eli Lilly and Company
• AstraZeneca plc
• GlaxoSmithKline plc
• Sanofi SA
• Novartis AG
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Sandoz International GmbH
• Lupin Limited
• Cipla Limited
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals PLC
• Alkem Laboratories Ltd.
• Torrent Pharmaceuticals Ltd.
• Zydus Lifesciences Limited

結論與建議

Global Postpartum Depression Market size was valued at USD 4.21 Billion in 2024 and is poised to grow from USD 4.68 Billion in 2025 to USD 10.95 Billion by 2033, growing at a CAGR of 11.2% during the forecast period (2026-2033).

The global postpartum depression (PPD) market encompasses pharmaceuticals, digital therapeutics, and support services designed to diagnose and treat depressive episodes occurring after childbirth. With approximately one in seven mothers affected, the condition poses a significant economic burden due to productivity losses. Previously characterized by a fragmented landscape dominated by generic antidepressants, the market has evolved as increased awareness and epidemiological studies prompted enhanced screening and diagnosis. The rise of digital health solutions is a pivotal trend, facilitating scalable treatment options. As healthcare providers embrace tele-psychiatry for reimbursement, startups are leveraging AI tools for early risk identification. Additionally, pharmaceutical companies are partnering with digital platforms to incorporate adherence monitoring apps, creating a collaborative ecosystem that improves patient access and market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Postpartum Depression market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Postpartum Depression Market Segments Analysis

Global postpartum depression market is segmented by treatment type, drug class, route of administration, distribution channel, end user and region. Based on treatment type, the market is segmented into pharmacotherapy, psychotherapy, neuromodulation therapy and combination therapy. Based on drug class, the market is segmented into selective serotonin reuptake inhibitors (SSRIs), neuroactive steroids, serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs) and others. based on route of administration, the market is segmented into oral, intravenous (IV) and intranasal. based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. based on end user, the market is segmented into hospitals, specialty clinics, ambulatory care centers and home care settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Postpartum Depression Market

The Global Postpartum Depression market is significantly influenced by heightened awareness and education initiatives aimed at promoting early identification of the condition. Proactive screening programs have emerged, enabling mothers to receive timely therapeutic interventions that mitigate long-term effects. Healthcare professionals are incorporating routine mental health evaluations into postnatal care, creating a supportive atmosphere where mothers feel comfortable discussing their symptoms. This increased visibility not only leads to better health outcomes for patients but also boosts the demand for various diagnostic tools, counseling services, and medication options. Consequently, this fosters market growth through greater utilization and acceptance of specialized treatment pathways.

Restraints in the Global Postpartum Depression Market

The global postpartum depression market faces significant challenges due to ongoing societal stigma and deeply ingrained cultural misconceptions regarding mental health. Many women find it difficult to recognize and admit symptoms of postpartum depression, often fearing that seeking help may be perceived as a personal failing. This leads to isolation and untreated conditions, severely limiting access to therapeutic interventions, counseling services, and pharmaceutical treatments. Furthermore, the lack of comprehensive community education initiatives amplifies these fears, stifling open communication about maternal mental health. Consequently, these factors collectively hinder the market's growth and decrease the overall demand for necessary support and treatments.

Market Trends of the Global Postpartum Depression Market

The Global Postpartum Depression market is witnessing a significant trend toward the adoption of digital therapeutics, propelled by the increasing acceptance of telehealth and mobile health solutions. Clinicians are increasingly incorporating evidence-based app-led interventions that offer cognitive-behavioral therapy, mood tracking, and peer support, enhancing patient engagement and eliminating geographical barriers. These innovative platforms enable personalized treatment pathways through advanced data analytics, fostering a tailored approach to care. As regulatory frameworks adapt to include software-as-medical-device approvals, healthcare providers are gaining confidence in the safety and efficacy of virtual care solutions, leading to expanded market opportunities and improved accessibility for affected individuals.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Postpartum Depression Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Pharmacotherapy
• Psychotherapy
• Neuromodulation Therapy
• Combination Therapy

Global Postpartum Depression Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Neuroactive Steroids
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Tricyclic Antidepressants (TCAs)
• Others

Global Postpartum Depression Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous (IV)
• Intranasal

Global Postpartum Depression Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Postpartum Depression Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Ambulatory Care Centers
• Home Care Settings

Global Postpartum Depression Market Size & CAGR (2026-2033)

• North America (Treatment Type, Drug Class, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Treatment Type, Drug Class, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Drug Class, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Drug Class, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Drug Class, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Sage Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkem Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations